Continuing Education Activity

Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy that accounts for a minority of lung cancers yet contributes disproportionately to cancer mortality. This activity details the epidemiology, strong associations with tobacco exposure, key molecular features, such as TP53 and RB1 loss, and the typical presentation of SCLC with advanced or metastatic disease. Diagnostic strategies, including imaging, histopathology, and staging, are also discussed alongside current management approaches for limited- and extensive-stage disease.

This course reviews the evolving standards of care, including the integration of chemo-immunotherapy and the recent addition of consolidation durvalumab following chemoradiotherapy. Participants will also gain an understanding of the clinical presentations, appropriate diagnostic pathways, evidence-based treatment strategies, and complications associated with SCLC, such as paraneoplastic syndromes. This activity for healthcare professionals is designed to enhance the learner's competence in identifying SCLC, performing the recommended evaluation, staying aware of ongoing clinical trials, and implementing an appropriate interprofessional approach when managing this condition, thereby enhancing patient outcomes in this high-risk population.

Objectives:

• Identify characteristic presentations of small cell lung cancer.
• Apply evidence-based diagnostic pathways for the staging of small cell lung cancer.
• Select guideline-concordant treatment strategies for the treatment of small cell lung cancer.
• Collaborate with the interprofessional team to improve care coordination and outcomes for patients affected by small cell lung cancer.

Introduction

Lung cancer remains the most commonly diagnosed malignancy worldwide and the leading cause of cancer-related mortality, accounting for approximately 20% of all cancer deaths.[WHO IARC. Lung Cancer. 2026] Histologic classification divides lung cancer into 2 primary types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with SCLC comprising approximately 15% of cases.[1] Despite its lower prevalence, SCLC is a highly aggressive, high-grade neuroendocrine tumor arising from pulmonary neuroendocrine cells within the bronchial epithelium, most often in the central bronchus. Rapid growth, early metastatic spread, and poor survival characterize this malignancy, with most patients presenting with metastatic disease at diagnosis.[2]

Management strategies depend on disease stage. Limited-stage disease has relied for the past 30 years on concurrent chemoradiotherapy with a platinum-etoposide regimen as the standard curative-intent approach. Extensive-stage disease typically requires palliative chemo-immunotherapy. The ADRIATIC trial in 2024 demonstrated a significant survival benefit with consolidation durvalumab following chemoradiotherapy in limited-stage disease, marking the first major therapeutic advance in decades.[3][4] Despite these developments, the prognosis remains poor. The World Health Organisation (WHO) has designated SCLC as a recalcitrant disease, underscoring the need for continued research to improve outcomes.[5]

Etiology

All lung cancers demonstrate an association with tobacco smoking, with SCLC showing a particularly strong link.[1] Cigarette smoke contains numerous carcinogens, including polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, benzene, arsenic, and acetaldehyde.[6] Risk is substantially higher among current smokers, with an odds ratio of 42.0 (95% CI: 21.7–81.2), compared with former smokers, who have an odds ratio of 17.1 (95% CI: 9.5–31.0).[8] These findings underscore the critical importance of smoking cessation, although lifetime risk does not return to baseline even after cessation.[1] Tobacco control measures implemented between 1970 and 2022 in the United States have been estimated to prevent 3,856,240 lung cancer deaths.[7]

A minority of cases, approximately 2% to 3%, occur in individuals without a history of tobacco use, with background radon exposure considered a contributing factor.[1] Molecular alterations further characterize the disease, with TP53 mutations present in up to 90% of cases, representing a hallmark driven primarily by tobacco-related carcinogenesis rather than radon exposure.[8] In addition, SCLC may arise through histologic transformation from epidermal growth factor receptor (EGFR)–mutant NSCLC.[9]

Epidemiology

Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting for more than 1,800,000 deaths, and in the United States, with more than 127,000 deaths reported in 2022.[WHO IARC. Global Cancer Observatory. 2026] In the United States, lung cancer ranks as the second most commonly diagnosed malignancy, representing 8.8% and 10.4% of cancer diagnoses in men and women, respectively.[WHO IARC. Global Cancer Observatory. 2026]

SCLC accounts for approximately 15% of lung cancer cases, with an incidence of 4.6 per 100,000 in 2022.[NCI. All Cancer Sites Combined Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2022] Tobacco smoking contributes to 95% of cases, and trends in incidence and mortality reflect changes in smoking behavior, typically with a lag of 30 years. Historically, the higher incidence among men, representing 68.3% of cases in 1975, has declined to below that of women, at 47.4% in 2019.[1] Slower smoking cessation among women and possible increased susceptibility may contribute to this shift.[1] Socioeconomic disparities also influence disease patterns, as smoking prevalence remains higher among individuals of lower socioeconomic status, a relationship that persists even after adjusting for smoking behavior.[1][2]

In contrast to NSCLC and overall lung cancer trends, individuals of African ancestry in the United States show lower incidence rates of SCLC compared with those of European ancestry, at 5.2 versus 6.4 per 100,000 in 2019, and demonstrate better median survival, reported as 7.8% versus 5.8%, despite disparities in healthcare access.[2] The underlying genetic contributors to these differences remain poorly defined.

Prognosis for SCLC remains poor. Although initial responses to therapy frequently occur, relapse remains common. Survival outcomes have improved modestly over time, with 1-year survival increasing from 23% during 1975–1979 to 30.8% during 2010 to 2019, and 5-year survival increasing from 3.6% to 6.8% over the same periods.[1] Current United States Preventive Services Task Force (USPSTF) guidelines from 2021 recommend annual low-dose CT screening for adults aged 50 to 80 with a smoking history of at least 20 pack-years, significantly expanding the eligible screening population compared with earlier criteria.

Pathophysiology

SCLC typically occurs in the central airways and, with a short doubling time and high mitotic rate, is considered aggressive. The cancer arises from the epithelium and infiltrates the submucosa. SCLC can compress the bronchus as the mass grows, causing breathlessness or stridor. The typical presentation is of a large hilar mass with bulky mediastinal lymphadenopathy. Symptoms are often not produced until late in the disease course and occur from complications, eg, lung collapse, postobstructive infection, or bleeding. SCLC is metastatic at presentation in two-thirds of cases, and the most common sites of metastases at presentation are liver (31.6%), bone (23.7%), brain (16.4%), distant lymph nodes (14.0%), and contralateral lung (13.9%).[1]

Although most SCLC cases are associated with tobacco smoking, most smokers do not develop this malignancy. Key molecular drivers include loss of the RB1 tumor suppressor gene and mutations in TP53 located at 17p13.1. Loss of RB1 removes a critical cell-cycle regulator, enabling uncontrolled cellular proliferation, while TP53 mutations disrupt apoptotic signaling. Both alterations generally arise as acquired, rather than germline, defects. Nearly all SCLC tumors demonstrate deletion within the short arm of chromosome 3p, a region that contains the tumor suppressor gene FHIT.[3] These molecular abnormalities collectively contribute to genomic instability, aggressive tumor behavior, and the rapid growth characteristic of this disease.

Histopathology

The WHO classifies SCLC as a high-grade, poorly differentiated neuroendocrine tumor.[4] Other tumors in this category include (LCNC), which falls under NSCLC, and typical and atypical carcinoid tumors, representing low- and intermediate-grade neoplasms, respectively (see Image. SCLC Versus NSCLC).

SCLC is primarily diagnosed through light microscopy. Tumor cells are small, approximately 2 to 3 times the size of resting lymphocytes, with scant cytoplasm, finely granular nuclear chromatin, and absent or faint nucleoli. These cells exhibit a high mitotic rate and frequent areas of necrosis. When present alone, the tumor is historically referred to as oat cell carcinoma, but it can also occur in combined subtypes with features of squamous cell carcinoma, adenocarcinoma, or large cell carcinoma.[4] Originating from epithelial cells, up to 90% of tumors show immunoreactivity for keratin and epithelial membrane antigen.[4] Neuroendocrine markers, including chromogranin A, synaptophysin, and neural cell adhesion molecule (NCAM)/CD56, often confirm the diagnosis, while thyroid transcription factor-1 (TTF1) is frequently expressed and helps distinguish SCLC from other neuroendocrine tumors.[4][10]

Immunohistochemical studies have identified four molecular subtypes of small cell lung cancer.[10] SCLC-A and SCLC-N exhibit high expression of neuroendocrine transcription factors ASCL1 and NEUROD1, respectively, and show strong positivity for chromogranin, synaptophysin, and NCAM. SCLC-P expresses POU2F3, a gene associated with pulmonary tuft cells in the peripheral lung parenchyma, and demonstrates fewer neuroendocrine markers. SCLC-I lacks these markers entirely and instead expresses inflammatory genes for human leukocyte antigens and immune checkpoints, eg, programmed cell death ligand 1 (PD-L1). SCLC-P has demonstrated high sensitivity to cisplatin, whereas SCLC-I tends to resist chemotherapy and instead responds to immune checkpoint inhibitors.[5] These molecular insights are driving the development of novel targeted therapies, and ongoing clinical trials aim to expand treatment options for each subtype.

History and Physical

Clinical History

A typical presentation involves a patient older than 70 years who is a current smoker. Many of these patients have chronic obstructive pulmonary disease (COPD) and multiple cardiovascular comorbidities. Symptoms depend on the characteristics and location of the primary tumor but often include progressive dyspnea, chronic cough, hemoptysis, chest pain, weight loss, and fatigue. Clinicians should specifically inquire about a newly hoarse voice, which may indicate recurrent laryngeal nerve involvement from local intrathoracic tumor extension. Facial plethora and distended neck veins may suggest superior vena cava obstruction (SVCO), which can be confirmed by a positive Pemberton sign—facial congestion, cyanosis, and respiratory distress after 1 minute with the arms raised to 180 degrees.[6]

Metastatic spread occurs most commonly to the brain, liver, adrenal glands, bone, and bone marrow. The history should explore symptoms at these sites, eg, neurological deficits, right upper-quadrant or liver-capsule pain, or localized bony pain. Detailed information about smoking history, including passive exposure, occupational risk factors, eg, radon exposure, and family history of lung cancer, should be obtained.

Assessment of the patient’s Eastern Cooperative Oncology Group (ECOG) performance status is critical, as this guides treatment selection and intensity. Clinicians should also evaluate for paraneoplastic syndromes, which are more common in SCLC than in other lung cancers. These may include proximal muscle weakness with paradoxical improvement on repeated activity, suggestive of Lambert-Eaton myasthenic syndrome, and symptoms of hyponatremia—confusion, nausea, or headache—indicative of syndrome of inappropriate antidiuretic hormone (SIADH).

Physical Examination

Examination should begin with a general inspection for cachexia. Signs of chronic tobacco use, eg, tar staining on the fingertips and tobacco odor, should be noted. Digital clubbing is less common in SCLC than in NSCLC, particularly adenocarcinoma, reflecting the neuroendocrine origin of SCLC. The thorax should be exposed to inspect for masses, asymmetry, and hyperinflation. The neck and supraclavicular regions should be examined for distended veins suggesting superior vena cava obstruction and palpated for enlarged lymph nodes. Lung auscultation and percussion should be performed to assess for abnormal breath sounds, vibrations, or dullness. The abdomen should be palpated, noting any nodular liver edge.

Clinicians should remain alert for signs of paraneoplastic syndromes, including neuromuscular or metabolic abnormalities. Proximal muscle weakness improving with repeated activity may indicate Lambert-Eaton myasthenic syndrome, while symptoms of hyponatremia, eg, confusion, nausea, and headache, suggest the syndrome of inappropriate antidiuretic hormone secretion. A thorough physical assessment, in conjunction with a detailed history, ensures early recognition of local tumor effects, metastases, and paraneoplastic phenomena, thereby guiding timely diagnosis and management.

Evaluation

Patients presenting with symptoms suggestive of lung cancer typically undergo a plain chest radiograph as an initial assessment. Sensitivity for lung cancer detection with chest x-ray has been reported at 81% (95% CI: 74–87%) and specificity at 68% (95% CI: 49–87%), indicating that radiography alone is insufficient for definitive diagnosis.[11] Consequently, a contrast-enhanced CT scan of the thorax, extending from the neck to the upper adrenal glands, is recommended by multiple national guidelines.[12][NICE. Lung Cancer: Diagnosis and Management. 2024] In asymptomatic individuals, the National Lung Screening Trial demonstrated CT sensitivity of 93.8% and specificity of 73.4%, highlighting its superior ability to detect early-stage disease.[13]

Initial laboratory evaluation should include full blood count, urea and electrolytes, liver function tests, C-reactive protein, and adjusted calcium. These tests help identify concurrent infections, paraneoplastic syndromes, and suggest the potential presence of metastatic disease. "Liquid biopsy," testing serum for circulating tumor DNA (ctDNA), has emerged as a tool for treatment monitoring, minimal residual disease assessment, and detection of transformation from EGFR-mutant NSCLC to SCLC. However, for SCLC, this currently does not provide the same range of actionable therapeutic targets as in NSCLC, where driver mutations (EGFR, ALK, ROS1) can guide targeted therapy selection.[14]

Assessment for metastatic disease typically involves ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-CT, which combines PET with CT to localize areas of hypermetabolic activity using intravenously administered FDG. While PET-CT is sensitive, false positives and false negatives can occur, and findings that would alter management should be confirmed pathologically.[8] Staging is performed using the TNM system, which is now preferred over the historical Veterans Administration Lung Study Group (VALSG) classification of limited and extensive disease because of its superior prognostic value (see Image. Characteristic SCLC CT Findings).

Histopathological confirmation from tissue sampling remains the diagnostic cornerstone.[15] The choice of modality depends on the location and extent of the disease. For the typical central presentation of SCLC with mediastinal or hilar lymphadenopathy, which represents the vast majority of cases, convex-probe endobronchial ultrasound-guided TBNA (CP-EBUS-TBNA) is the preferred approach, as it simultaneously provides tissue diagnosis and mediastinal staging in a single bronchoscopic procedure. An endobronchial biopsy during bronchoscopy is an alternative when the tumor is visible in the central airways. In the rare instance that SCLC presents as a peripheral lesion without accessible mediastinal disease, transthoracic needle aspiration (CT- or ultrasound-guided) may be considered. However, it carries a higher risk of pneumothorax than bronchoscopic techniques and should be used selectively.

Following tissue confirmation, patients typically undergo a brain magnetic resonance imaging (MRI) with gadolinium contrast to assess for metastases, given their high incidence in SCLC.[16] Individuals considered for surgical resection or curative-intent radiotherapy should also undergo comprehensive pulmonary function testing, including spirometry and gas transfer measurements, to assess procedural fitness and optimize perioperative planning.

Treatment / Management

Treatment recommendations for SCLC are outlined in national and international guidelines, eg, American and European.[8][17] All patients are encouraged to engage with smoking cessation at the earliest possible opportunity, but this is not required before beginning treatment (see Image. SCLC Staging and Treatment Algorithm)

Limited Stage

Limited-stage disease is defined as potentially curable cancers. Limited-stage disease is therefore not metastatic, and the disease is limited to a single radiation field, allowing curative intent treatment with concurrent chemo-radiotherapy. Traditionally, this was a disease limited to 1 hemithorax, but the definition has broadened as radiotherapy capabilities have grown.

The current standard chemotherapy regimen for all limited-stage disease SCLC is a combination of cisplatin and etoposide. Standard dosing is cisplatin 60 to 80 mg/m² on day 1 and etoposide 100 to 120 mg/m² on days 1, 2, and 3 of a 3-week cycle. Initial response rates, defined as a tumor reduction of at least 30%, range from 70% to 90%.[18] No evidence of a survival benefit has been demonstrated for extending chemotherapy beyond 4 cycles.[8] Furthermore, carboplatin can replace cisplatin, as survival outcomes are similar, although carboplatin causes more myelosuppression, whereas cisplatin causes more nausea, vomiting, neurotoxicity, and nephrotoxicity.

The addition of concurrent radiation significantly increases local control and overall survival. Early concurrent chemo-radiotherapy (starting from cycle 1 or 2) is the preferred standard; sequential radiotherapy may be considered for patients unable to tolerate concurrent therapy. The radiation field covers both the original tumor and any involved lymph nodes.[19] Radiation can be administered sequentially rather than concurrently in frail patients, in whom adverse effects may be more detrimental.[8][17] The dosing standard is 45 Gy over 30 fractions in 3 weeks (twice daily), because the CONVERT trial was unable to demonstrate superiority of once-daily dosing (66 Gy over 33 fractions in 6.5 weeks).[18] 

In 2024, the ADRIATIC trial reported significant increases in overall and progression-free survival with the addition of consolidation immunotherapy compared to conventional chemo-radiotherapy alone.[20] Notably, the addition of tremelimumab (a CTLA-4 inhibitor) to durvalumab did not provide further benefit over durvalumab monotherapy in the ADRIATIC trial. The novel therapy is the immune checkpoint inhibitor durvalumab, an immunoglobulin G1 kappa monoclonal antibody that binds to PD-L1 on cancer cells and can be used for up to 2 years.

Prophylactic cranial irradiation (PCI) is indicated for patients with a complete or partial response to chemotherapy because PCI has been shown to decrease the incidence of brain metastases and increase overall survival.[19] Surveillance MRI of the brain is an emerging alternative to PCI in selected limited-stage SCLC patients, particularly those at higher risk of neurocognitive adverse effects from cranial irradiation. However, uncertainties remain due to a lack of evidence, for example, in patients older than 70, in those who are frail, or in those with stage I to II SCLC who are less at risk of developing brain metastases. The recommended dose is 25 Gy in 10 daily fractions.

Less than 5% of patients present with TNM stage I or II disease (specifically T1-2, N0, M0) and therefore may undergo curative lobectomy. Full mediastinal staging is required at EBUS or mediastinoscopy; sublobar resection is not recommended; and a full lymph node dissection should be carried out intra-operatively. Adjuvant chemotherapy is recommended for all cases, with the addition of radiotherapy for incomplete resection margins or unexpected lymph node positivity.[8][17]

Extensive Stage 

Most patients present with metastatic disease, and this is not curable. Treatments for these patients are palliative, focusing on prolonging life and maintaining quality of life. First-line treatment is with chemo-immunotherapy. The chemotherapy is cisplatin with etoposide, although carboplatin is often favoured over cisplatin due to its reduced adverse effect profile, which benefits the frailer cohort of patients that present with ES. Noninferiority has also been shown for irinotecan,[21] topotecan,[22] or gemcitabine,[23] in place of etoposide. Two double-blind, phase 3, randomised controlled trials have recently reported evidence that has changed the management of extensive-stage SCLC.

Evidence has demonstrated that durvalumab or atezolizumab, immune checkpoint inhibitors, should be added to conventional chemotherapy for 4 cycles in less frail patients (performance status 0 to 1).[24][15] This should be followed by maintenance immunotherapy. The ongoing PRISM trial (SWOG 2409) is investigating whether SCLC subtypes respond to the additional immune checkpoint inhibitors saruparib, ceralasertib, or monalizumab after standard treatment with chemotherapy and durvalumab. Patients with a performance status of 2 or greater can be considered for chemotherapy alone, or simply for best supportive care, depending on frailty and comorbidities. 

PCI has traditionally been offered to patients with stage IV SCLC who are younger than 75, have a performance status of 0 to 2, and have not progressed after first-line therapy. However, evidence has challenged its survival benefit in extensive-stage SCLC, and surveillance with serial brain MRI scans is now considered an acceptable alternative per current National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines. The ongoing MAVERICK trial (SWOG 1827) will further inform this practice.

Relapsed Small Cell Lung Cancer

Initial response to first-line therapy is common, but so is relapse. If the relapse happens within 90 days of the last chemotherapy, the cancer is said to be platinum-resistant. For these patients, continuation of chemotherapy with a single agent of topotecan, lurbinectedin, or tarlatamab is recommended.[20] Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, received FDA accelerated approval in May 2024 for relapsed extensive-stage SCLC, representing a novel immunotherapy mechanism distinct from conventional checkpoint inhibition. If more than 90 days, then rechallenging with platinum-based chemotherapy and the addition of immunotherapies, if not already added, may also be considered, based on the patient's frailty and comorbidities.

Brain Metastases

The best treatment for brain metastases from SCLC has not been established. Guidelines recommend treating asymptomatic brain metastases with the same treatment as the thoracic disease (ie, chemo-radiotherapy) because this crosses the blood-brain barrier.[25] They recommend treating symptomatic brain metastases with either whole brain radiotherapy (WBRT) or stereotactic radiosurgery (STRS), also known as stereotactic ablative radiotherapy (SABR). A meta-analysis of 7 retrospective studies, totalling 18,050 patients, reported similar overall survival (hazard ratio, 0.87; 95% CI, 0.76-1.01) with WBRT versus STRS.[26]

Differential Diagnosis

The diagnosis of SCLC requires exclusion of several conditions that may present with overlapping clinical, radiographic, or histopathological features, including:

• Large cell neuroendocrine carcinoma (LCNEC): This condition shares neuroendocrine histology and may be morphologically similar to SCLC on small biopsy specimens. The distinction relies on immunohistochemistry, with LCNEC typically showing larger cell size, more abundant cytoplasm, prominent nucleoli, and a lower Ki-67 proliferation index than SCLC (which commonly exceeds 80%). LCNEC is classified as NSCLC and managed differently.[25]
• Typical and atypical carcinoid tumors: Carcinoid tumors are low- and intermediate-grade neuroendocrine neoplasms distinguished from SCLC by mitotic rate (<2/10 HPF for typical; 2–10/10 HPF for atypical) and Ki-67 index, and carry a substantially better prognosis.
• Primary mediastinal lymphoma: This condition may present as a bulky central mediastinal mass with PET avidity and systemic symptoms mimicking SCLC. Tissue biopsy with flow cytometry and immunophenotyping is diagnostic.
• Thymoma and thymic carcinoma: These tumors arise in the anterior mediastinum and may cause paraneoplastic syndromes, notably myasthenia gravis, which must be distinguished from Lambert-Eaton myasthenic syndrome in the SCLC context.
• Metastatic disease to the mediastinum: Mediastinal metastasis from extrathoracic primaries (melanoma, renal cell carcinoma, breast) can mimic SCLC on imaging and requires IHC panel differentiation.

Surgical Oncology

Surgery plays a very limited role in SCLC. Fewer than 5% of patients present with disease amenable to surgical resection, specifically those with TNM stage I or II disease (T1-2 N0 M0), because the vast majority have centrally located tumors with mediastinal involvement or metastatic disease at diagnosis.[NCCN. Small Cell Lung Cancer. 2026]Patient Selection and Preoperative StagingBefore surgery is considered, rigorous preoperative mediastinal staging is mandatory. CP-EBUS-TBNA or mediastinoscopy must be performed, as occult nodal disease is common and would preclude resection.[NCCN. Small Cell Lung Cancer. 2026]

Surgical Procedure

Lobectomy is the recommended surgical resection for SCLC. Sublobar resection is not recommended due to the high risk of incomplete resection and local recurrence.[27] A complete systematic mediastinal lymph node dissection must be performed intra-operatively, as accurate pathological nodal staging determines adjuvant treatment decisions and prognosis.

Adjuvant Treatment

Adjuvant platinum-etoposide chemotherapy is recommended for all patients following complete surgical resection, regardless of pathological stage, given the high risk of systemic micrometastatic disease.[NCCN. Small Cell Lung Cancer. 2025] Performing 4 cycles is standard. Postoperative radiotherapy is recommended for incomplete resection margins (R1/R2) or unexpected intraoperative lymph node positivity (upstaged N1 or N2). The role of adjuvant durvalumab consolidation immunotherapy following surgery has not yet been established in dedicated surgical SCLC trials.OutcomesThe 5-year overall survival rates for surgically resected stage I SCLC range from 40% to 60% in retrospective series, reflecting the highly selected nature of these cohorts.[30] Recurrence rates remain high even after complete resection, underscoring the importance of adjuvant chemotherapy and close surveillance with CT chest and brain MRI.

Radiation Oncology

Radiotherapy plays a central, multifaceted role in SCLC management, contributing to curative-intent treatment in limited-stage disease and to palliative symptom control in extensive-stage disease.

Thoracic Radiotherapy in Limited-Stage SCLC

Concurrent thoracic radiotherapy, when added to platinum-etoposide chemotherapy, significantly improves local control and overall survival in limited-stage SCLC. A landmark meta-analysis demonstrated a 5.4% absolute improvement in 3-year overall survival with the addition of thoracic radiotherapy.[28] Early concurrent chemo-radiotherapy, starting radiotherapy with cycle 1 or 2 of chemotherapy, is the preferred standard. Sequential radiotherapy may be considered for patients unable to tolerate concurrent treatment due to frailty or significant comorbidity.

The standard radiation dose fractionation regimen is 45 Gy delivered in 30 fractions over 3 weeks using a twice-daily (hyperfractionated accelerated) schedule, as established by the CONVERT trial, which found no superiority for once-daily 66 Gy/33 fractions.[29] Radiation fields should encompass the primary tumor and all involved lymph node stations on pre-treatment PET-CT or CT staging.

Modern radiotherapy planning uses intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT). A 4-dimensional CT (4D-CT) simulation characterises respiratory tumor motion. Key organs at risk (OAR) dose constraints include:

• Spinal cord: Maximum dose ≤45 Gy
• Lungs (combined): Mean lung dose (MLD) ≤20 Gy; V20 <35% [29]
• Esophagus: Mean dose ≤34 Gy; V60 <17%
• Heart: Mean dose ≤26 Gy; V30 <46%

Prophylactic Cranial Irradiation 

PCI reduces the incidence of brain metastases and improves overall survival in patients with limited-stage SCLC who achieve a complete or partial response to CRT, as demonstrated by a landmark meta-analysis.[30] Standard dose is 25 Gy in 10 daily fractions. PCI carries a risk of neurocognitive toxicity. In extensive-stage SCLC, brain MRI surveillance is now an acceptable alternative to PCI, per NCCN (2024) and ESMO (2023) guidelines, following the JCOG0504 randomised trial.[31]

Palliative Radiotherapy

Palliative radiotherapy is important for symptom control in extensive-stage SCLC. Common indications include:

• Bone metastases: 8 Gy single fraction or 20 Gy/5 fractions for pain palliation
• SVCO: Emergency palliative radiation therapy for patients not suitable for systemic chemotherapy
• Brain metastases: WBRT (20 Gy/5 fx or 30 Gy/10 fx) or stereotactic radiosurgery (SRS/SABR) [32]
• Endobronchial obstruction: Short-course radiation therapy or brachytherapy for central airway disease

Pertinent Studies and Ongoing Trials

The management of SCLC has been shaped by a series of landmark clinical trials, with significant new evidence emerging in 2024. The following summarises the key trials underpinning current practice and the most important ongoing studies.

Landmark Completed Trials

CONVERT Trial 

Phase III randomized control trial comparing twice-daily 45 Gy/30 fractions with once-daily 66 Gy/33 fractions, both concurrent with platinum-etoposide in limited-stage SCLC. No significant difference in overall survival (median 25 vs 28 months). Twice-daily regimen remains the standard.[29][18]

ADRIATIC Trial

Double-blind phase 3 randomized control trial, 730 patients with limited-stage SCLC following concurrent CRT, randomised to durvalumab, durvalumab plus tremelimumab, or placebo. Durvalumab monotherapy versus placebo: median overall survival of 55.9 versus 33.4 months (HR 0.73; 95% CI 0.57–0.93; P = 0.0104); 3-year overall survival approximately 57% versus approximately 48%. The addition of tremelimumab to durvalumab showed no additional benefit over durvalumab alone. First major limited-stage SCLC treatment advance in over 30 years.[3]

IMPOWER133 Trial 

Phase 3 randomized controlled trial, 403 patients with treatment-naive extensive-stage SCLC. Carboplatin/etoposide plus atezolizumab versus placebo: median overall survival 12.3 versus 10.3 months (HR 0.70; 95% CI 0.54–0.91; P = 0.007). Established atezolizumab as the first immunotherapy approval for extensive-stage SCLC.[15]

CASPIAN Trial

Phase 3 randomized controlled trial, 805 patients with treatment-naive extensive-stage SCLC. Durvalumab plus platinum-etoposide versus chemotherapy alone: median overall survival 12.9 versus 10.5 months (HR 0.75; 95% CI 0.62–0.91; P = 0.0032). 3-year overall survival: 17.6% in the durvalumab arm versus 5.8% in the control arm. Addition of tremelimumab did not improve outcomes over durvalumab alone.[24][33]

DeLLphi-301 Trial 

Phase 2 single-arm trial, 220 patients with extensive-stage SCLC after 2 or more prior lines. Tarlatamab (DLL3-targeted bispecific T-cell engager) demonstrated 40% ORR in the 10 mg cohort; median duration of response was 9.7 months. Led to FDA accelerated approval of tarlatamab in May 2024, the first BiTE approved in thoracic oncology.[34]

JCOG0504 Trial 

Japanese phase 3 randomised noninferiority trial, 224 patients with extensive-stage SCLC responding to first-line platinum chemotherapy. MRI brain surveillance is noninferior to PCI in terms of overall survival (median overall survival: 11.6 vs 13.7 months; noninferiority margin met). Prompted NCCN (2024) and ESMO (2023) to accept MRI surveillance as an acceptable alternative to PCI in extensive-stage SCLC.[35]

Ongoing Trials

MAVERICK trial

Phase 3 randomized controlled trial comparing MRI brain surveillance versus PCI in limited-stage SCLC patients who have responded to CRT. This study will definitively establish whether MRI surveillance is noninferior to PCI in limited-stage SCLC and will assess neurocognitive outcomes in both arms. Results awaited.[ClinicalTrials.gov. MAVERICK Trial]

PRISM trial 

Ongoing randomised trial investigating whether SCLC molecular subtypes (SCLC-A, N, P, I) predict response to additional immune checkpoint inhibitors (saruparib, ceralasertib, monalizumab) after standard chemo-immunotherapy with durvalumab in extensive-stage SCLC. Aims to establish biomarker-driven treatment selection.[ClinicalTrials.gov. PRISM Trial]

Treatment Planning

Treatment planning in SCLC requires close interprofessional team collaboration, with decisions tailored to disease stage, performance status, pulmonary reserve, and patient preference.

Systemic Treatment Planning

Prior to initiating chemotherapy, baseline assessment should include full blood count, renal function (eGFR is essential for cisplatin dosing), liver function, and ECOG performance status. Cisplatin is contraindicated if eGFR is less than 50 mL/min/1.73m²; carboplatin dosed by AUC using the Calvert formula is the preferred substitute. Audiometry should be considered in patients with preexisting hearing loss or concurrent nephrotoxic medications. Aggressive prehydration and posthydration protocols are mandatory with cisplatin to prevent nephrotoxicity.[36][37][36]

For patients receiving immunotherapy (durvalumab or atezolizumab), baseline thyroid function, fasting glucose, cortisol, and autoimmune screen should be documented before treatment, as immune-related adverse events affecting endocrine, pulmonary, and gastrointestinal systems may develop during treatment.[38]

Radiation Treatment Planning — Limited Stage

Simulation is performed with the patient supine, arms raised, using CT simulation. A 4-dimensional CT (4D-CT) characterizes respiratory tumor motion and defines the internal target volume (ITV).[19] Key planning volumes:

• GTV (Gross Tumor Volume): Primary tumor and all PET-avid or CT-enlarged lymph node stations
• CTV (Clinical Target Volume): GTV plus 5–8 mm margin for microscopic extension
• PTV (Planning Target Volume): CTV plus respiratory motion and set-up uncertainty margin (5–10 mm)

IMRT or VMAT is preferred over 3D-CRT for superior dose conformality and OAR sparing.[19] Key dose constraints:

• Spinal cord: Max ≤45 Gy
• Lungs: MLD ≤20 Gy; V20 <35%
• Oesophagus: Mean dose ≤34 Gy; V60 <17%
• Heart: Mean dose ≤26 Gy; V30 <46%

PCI Planning

Standard whole-brain field arrangement; prescription 25 Gy in 10 daily fractions.[37] Hippocampal-sparing PCI (HS-PCI) using IMRT to reduce dose to hippocampal neural stem cells is under investigation in clinical trials as a strategy to reduce neurocognitive toxicity, but is not yet standard practice for SCLC-PCI.

Toxicity and Adverse Effect Management

Management of treatment-related toxicity is an integral component of SCLC care, requiring close collaboration between oncologists, pharmacists, and specialist nurses (see Image. Toxicity Management for SCLC Treatment).[39]

Cisplatin Toxicities

Adverse effects and toxicities associated with cisplatin include:

• Nephrotoxicity: Dose-dependent tubular injury is the most serious toxicity.[36] Preventive strategies against nephrotoxicity include aggressive pre- and posthydration (1–2 L of normal saline), avoidance of concurrent nephrotoxins (eg, NSAIDs, aminoglycosides), and eGFR monitoring before each cycle. Substitute carboplatin if eGFR falls below 50 mL/min/1.73m².[40]
• Electrolyte disturbances: Hypomagnesemia (most common), hypokalemia, and hypocalcemia due to renal tubular wasting. Regular monitoring and oral or IV supplementation are required.
• Ototoxicity: Sensorineural hearing loss and tinnitus, typically irreversible and cumulative.[36] Baseline audiometry in at-risk patients.
• Peripheral neuropathy: Sensory neuropathy (glove-and-stocking distribution), cumulative and potentially irreversible. Consider dose reduction or carboplatin substitution at grades ≥2.
• Nausea and vomiting: Cisplatin is highly emetogenic. Standard prophylaxis administers a 5-HT3 antagonist plus an NK1 receptor antagonist (aprepitant) plus dexamethasone on day 1, with continued antiemetics on days 2 to 4.[36][41]

Myelosuppression

Platinum-etoposide causes significant myelosuppression with nadir at 10to 14 days postcycle. Febrile neutropenia requires urgent hospitalisation and IV broad-spectrum antibiotics. Prophylactic G-CSF (filgrastim or pegfilgrastim) is recommended for regimens with a febrile neutropenia risk greater than 20%.FBC must be checked before each cycle with dose delays or reductions for grade 3 to 4 myelosuppression not recovering by the treatment date.[36]

Immune-Related Adverse Events from Checkpoint Inhibitors

Durvalumab and atezolizumab can cause immune-related adverse events (irAEs) affecting virtually any organ system.[42] Key irAEs in SCLC include:

• Immune-related pneumonitis: New breathlessness, cough, radiological infiltrates, must be distinguished from infection, progression, and radiation pneumonitis. The Common Terminology Criteria recommend the following management for Adverse Events (CTCAE) grades:

  • Grade 1: monitor
  • Grade 2: hold immune checkpoint inhibitors, oral prednisolone 1 mg/kg/day
  • Grade 3–4: permanently discontinue, high-dose IV methylprednisolone [42]
• Particular vigilance is needed in SCLC patients given underlying COPD and concurrent thoracic radiotherapy.

• Immune-related colitis: Diarrhea, abdominal pain. Same corticosteroid protocol by grade. Infliximab for steroid-refractory cases.
• Endocrine toxicities: Hypothyroidism is most common, which may be managed with levothyroxine. Hypophysitis and adrenal insufficiency are life-threatening if missed. Monitor thyroid function tests, morning cortisol, and fasting glucose throughout treatment.[42]
• Immune-related hepatitis: This adverse effect can be indicated by transaminase elevation; therefore, liver function tests should be monitored before each cycle. Corticosteroids for grade ≥2 (>3× upper limit of normal).
• Dermatological: Rash and pruritus (usually mild); rare severe reactions (eg, Stevens-Johnson syndrome) require immediate discontinuation of immune checkpoint inhibitors.

Radiation Toxicities

Acute toxicities that can occur during or immediately after CRT include:

• Radiation oesophagitis: Most common acute CRT toxicity. Odynophagia and dysphagia may be managed with analgesia, proton pump inhibitors, and nutritional support. Nasogastric tube feeding is used for grade 3.
• Acute radiation pneumonitis: May develop 4 to 12 weeks after radiation therapy. Breathlessness, cough, and fever are characteristic symptoms. Corticosteroids are recommended for symptomatic cases.

Late toxicities include radiation fibrosis (progressive dyspnea), esophageal stricture, cardiac toxicity (pericarditis, cardiomyopathy), and neurocognitive impairment following PCI, the primary rationale for investigating MRI surveillance as an alternative.[37]

Medical Oncology

Medical oncology is central to SCLC management at all stages. Systemic therapy decisions are guided by disease stage, performance status, comorbidities, and increasingly by molecular subtype.

First-Line Systemic Therapy for Extensive Stage Small Cell Lung Cancer

Standard first-line treatment for extensive-stage SCLC in patients with ECOG performance status 0 to 1 is chemo-immunotherapy consisting of carboplatin or cisplatin combined with etoposide, plus durvalumab[24] or atezolizumab, for 4 induction cycles, followed by maintenance immunotherapy until disease progression or unacceptable toxicity.[15][24][15] Carboplatin is frequently preferred due to its more favourable toxicity profile in this typically older adult, comorbid population. For ECOG performance status 2, chemotherapy alone is an option. For a performance status of 3 to 4, performing supportive care is typically most appropriate.

Second-Line and Subsequent Therapy for Relapsed Small Cell Lung Cancer

Treatment approaches recommended for the following platinum responses:

• Platinum-resistant relapse (<90 days): Topotecan,[43] lurbinectedin (35% ORR),[44] or tarlatamab (40% ORR; FDA accelerated approval May 2024; DLL3-targeted bispecific T-cell engager).[34]
• Platinum-sensitive relapse (>90 days): Rechallenge with platinum-etoposide is appropriate; add immunotherapy if not previously given. Single-agent second-line options remain available if rechallenge is not tolerated.

Biomarker-Driven Treatment Selection

SCLC currently lacks validated predictive biomarkers for routine clinical use. PD-L1 expression does not reliably predict response to immune checkpoint inhibitors. Molecular subtyping (SCLC-A, N, P, I) is under active investigation. The SCLC-I (inflammatory subtype) may preferentially respond to immune checkpoint inhibitors due to higher tumor mutational burden and an inflamed microenvironment. The PRISM trial (SWOG 2409-NCT06769126) is a prospective trial evaluating subtype-directed treatment. Tissue collection at diagnosis and at relapse for translational research is strongly encouraged.

Staging

Veterans Administration Lung Study Group 

The Veterans Administration Lung Study Group (VALSG) classification has been used historically and is still widely used clinically. This classification defines the limited and extensive stages by the following criteria:

• Limited stage: Disease confined to 1 hemithorax and regional lymph nodes (ipsilateral mediastinal and supraclavicular nodes), encompassable within a single radiotherapy field. Approximately 30% to 35% of patients are diagnosed.
• Extensive stage: Disease beyond the limited-stage definition, including contralateral lung, malignant pleural or pericardial effusion, and distant metastases. Approximately 65% to 70% of patients are diagnosed.

TNM Staging

TNM staging is the currently preferred classification system. Most guidelines, including NCCN and ESMO, now recommend TNM staging using the eighth edition of the IASLC/UICC classification, as it provides superior prognostic discrimination compared with VALSG.[45] In clinical practice, many interprofessional teams continue to use VALSG terminology alongside TNM staging, as treatment algorithms remain structured around limited vs extensive stage distinctions.Less than 5% of patients presenting with TNM stage I to II (T1-2 N0 M0) disease may be considered for surgical resection. Mediastinal staging with CP-EBUS or mediastinoscopy is required before any surgical consideration.

Prognosis

SCLC carries the worst prognosis of any lung cancer subtype and has been designated a "recalcitrant disease" by the WHO in recognition of the need for continued research investment.

For limited-stage SCLC, the addition of durvalumab consolidation to concurrent chemoradiotherapy in the ADRIATIC trial demonstrated a median overall survival of 55.9 months and a 3-year overall survival of approximately 57%, representing a meaningful advance over historical benchmarks.[3][20] Extensive-stage SCLC carries a substantially worse outlook. Despite initial chemosensitivity, relapse is almost universal, with disease progression typically occurring within 4 to 6 months of completing first-line chemo-immunotherapy. The CASPIAN trial reported a 3-year overall survival of 17.6% with durvalumab plus platinum-etoposide.[4]

Overall, 5-year survival across all stages remains below 7%. Adverse prognostic factors include extensive-stage disease, poor performance status (ECOG ≥2), elevated LDH, hyponatraemia (reflecting SIADH), and the presence of brain metastases at diagnosis. Patients who achieve a complete response to first-line therapy and maintain performance status have the greatest likelihood of prolonged survival.

Complications

Paraneoplastic Syndromes 

SCLC is the most common solid tumor to cause paraneoplastic syndromes due to its neuroendocrine origin (see Image. Paraneoplastic Syndromes in Small Cell Lung Cancer). Paraneoplastic syndromes can be caused by ectopic hormone production, as is the case in the most common, SIADH. This occurs in 15% to 40% of SCLC patients, in whom elevated antidiuretic hormone levels impair free-water excretion.[46] Findings will include hypotonic hyponatraemia with urinary sodium in excess of 20 mmol/L, and normal renal, hepatic, cardiac, pituitary, adrenal, and thyroid function, with euvolaemia (absence of hypotension, hypovolaemia, and oedema). SCLC is only one of many potential causes. Treatment with water restriction is usually effective.

Another common paraneoplastic syndrome is Cushing syndrome, occurring in 2% to 5% of patients.[46] Ectopic production of corticotropin (ACTH) results in elevated free cortisol levels. This can present with central obesity, easy bruising and thin skin, hirsuitism, and proximal muscle weakness. Findings may include difficult-to-control blood glucose, hypertension, and reduced mineral bone density. 

A different type of paraneoplastic syndrome can occur with the development of autoantibodies as part of the body's immune response to the cancer. Lambert-Eaton Myasthenic syndrome occurs in 1% to 3% of patients with SCLC, and 50% to 70% of cases are associated with SCLC.[47] It occurs when antibodies form to presynaptic voltage-gated calcium channels, causing proximal muscle weakness that classically affects the legs more than the arms (in contrast to myasthenia gravis, which affects the arms more than the legs). The weakness tends to improve on repeated testing. The autonomic nervous system is also involved in 75% of cases (dry mouth, blurred vision, postural hypotension). Treatment prioritises management of the underlying malignancy, as successful cancer treatment may improve Lambert-Eaton Myasthenic syndrome. For symptomatic relief, amifampridine (3,4-diaminopyridine) is the evidence-based first-line agent, acting by blocking voltage-gated potassium channels to increase acetylcholine release at the neuromuscular junction. Intravenous immunoglobulin or plasma exchange may be used for acute exacerbations or when cancer treatment is insufficient.

Superior Vena Cava Syndrome

Superior vena cava syndrome is a syndrome of compression of the superior vena cava, usually externally, by a mediastinal tumor, and is classically associated with SCLC. This condition presents with shortness of breath, facial swelling, and distended collateral veins of the neck and chest.[48] The initial management is urgent systemic chemotherapy, which acts rapidly on chemosensitive SCLC to relieve SVC compression. Dexamethasone may reduce edema. Endovascular SVC stenting may be required for immediate symptom relief in patients with severe symptoms or those unsuitable for prompt chemotherapy. Palliative radiotherapy may be used in patients unable to receive systemic therapy.

Tumor Lysis Syndrome

Tumor lysis syndrome is a syndrome of electrolyte disturbances resulting from the rapid apoptosis of cancer cells, typically seen in extended-stage SCLC.[4] This condition usually requires hospitalization to facilitate electrolyte replacement. The drugs allopurinol and rasburicase can be helpful in severe cases. 

Chemotherapy-Induced Myelosuppression

Chemotherapy-induced myelosuppression is characterized by anemia, neutropenia, or thrombocytopenia as a result of chemotherapy, usually the platinum-based component. This complication can present with fatigue and shortness of breath, opportunistic infections, and easy bleeding or a vasculitic rash, due to the loss of each respective cell line. Chemotherapy-induced myelosuppression is managed with prophylactic granulocyte colony-stimulating factor (G-CSF) injections and, if necessary, intravenous blood product replacement. 

Postoperative and Rehabilitation Care

Postoperative and rehabilitation care apply to the small minority of SCLC patients (<5%) who undergo lobectomy for stage I to II disease.[25][8]

Immediate Postoperative Care

Following lobectomy, patients are managed in a surgical high-dependency unit. Epidural analgesia or paravertebral nerve blocks are preferred over systemic opioids to preserve respiratory function. Low-molecular-weight heparin thrombosis prophylaxis commences once surgical haemostasis is confirmed. Early mobilisation and chest physiotherapy begin from day 1 to prevent atelectasis and pneumonia.

Pulmonary Rehabilitation

A structured pulmonary rehabilitation program, including supervised exercise training, breathlessness management, and patient education, should begin following discharge and continue throughout adjuvant chemotherapy. Formal rehabilitation assessment before discharge is recommended.[49][4]

Adjuvant Chemotherapy and Surveillance

Adjuvant platinum-etoposide chemotherapy should commence 4 to 6 weeks postoperatively when renal function, performance status, and haematological parameters are satisfactory.[17] Surveillance should involve a CT chest every 3 months for 2 years, then every 6 months for 5 years.[25] Brain MRI or PCI should be performed per guidelines. Active smoking cessation support should be provided throughout follow-up.

Consultations

SCLC management requires a comprehensive interprofessional team. Early specialist consultation optimises patient outcomes.[39]

Core Interprofessional Team

The following clinicians should be involved in developing treatment strategies for all patients with SCLC:

• Respiratory physician and interventional pulmonologist: Leads diagnostic workup, performs CP-EBUS-TBNA (tissue diagnosis + mediastinal staging), coordinates the lung cancer interprofessional team meeting, and manages concurrent pulmonary comorbidities.
• Medical oncologist: Systemic treatment planning and administration, including chemotherapy, immunotherapy, and relapsed disease management. Toxicity monitoring should also be performed.
• Clinical/radiation oncologist: Concurrent thoracic CRT in LS-SCLC, PCI or MRI surveillance planning, palliative RT for symptom control.
• Thoracic Surgeon: Evaluates <5% of patients (T1-2 N0 M0) for surgical resection. Input must be sought early to arrange preoperative mediastinal staging before treatment begins.
• Radiologist: Staging CT, PET-CT, MRI brain interpretation. CT-guided biopsy for peripheral lesions. RECIST 1.1 response assessment.
• Pathologist: Histopathological diagnosis, WHO classification, IHC (chromogranin A, synaptophysin, CD56, TTF-1, Ki-67), molecular subtyping (SCLC-A/N/P/I).
• Specialist lung cancer nurse: Patient's primary point of contact for coordinating care, providing education, and supporting advanced care planning.

Additional Consultations 

The following consultations may be needed if indicated:

• Neurology: Consult indicated for Lambert-Eaton myasthenic syndrome (EMG/NCS, VGCC antibodies), antineuronal paraneoplastic syndromes, and neurological complications of brain metastases.[50][47]
• Endocrinology: Consult indicated for ectopic ACTH Cushing syndrome (steroidogenesis inhibitors may be required), immune checkpoint inhibitors-related adrenal insufficiency/hypophysitis, and immune-related thyroid dysfunction.[51]
• Nephrology: Consult indicated for severe cisplatin nephrotoxicity or complex electrolyte disturbances.
• Palliative care: Consult indicated for early referral for all extended-stage SCLC patients from diagnosis; should not be reserved for end of life, as this improves quality of life and reduces unnecessary acute admissions.[52]
• Gastroenterology: Grade 3 to 4 immune checkpoint inhibitor-related colitis is an indication for gastroenterology consultation. Colonoscopy and biopsy are needed to exclude infection before escalating to infliximab.[38][51]
• Psychiatry and psychology: Anxiety, depression, and adjustment disorder are common in this poor-prognosis disease.
• Dietitian: Patients with cancer-related malnutrition, treatment-related nausea and anorexia, and significant weight loss should have a referral to a dietitian or nutritional clinician.

Deterrence and Patient Education

All patients should be encouraged to engage in smoking cessation at the earliest possible opportunity, as cessation improves outcomes across all stages of disease. Given the aggressive growth of SCLC, prompt medical evaluation remains essential when persistent red flag symptoms develop, including unexplained dry cough, hemoptysis, weight loss, and chest pain.

SCLC often remains asymptomatic until metastatic spread occurs, making early detection challenging. Individuals with a significant smoking history should participate in national lung cancer screening programs. Annual surveillance with low-dose CT scanning reduces lung cancer mortality among high-risk populations. The National Lung Screening Trial demonstrated that 3 annual low-dose CT scans achieved a 20% relative reduction in mortality compared with 3 annual chest radiographs in patients aged 55 to 74 with a smoking history exceeding 30 pack-years.[53] The NELSON trial confirmed similar findings in European populations using slightly different inclusion criteria, informing updated screening recommendations, including those from the American Cancer Society.[54][55]

Current United States Preventive Services Task Force guidance from 2021 recommends annual low-dose CT screening for adults aged 50 to 80 with a smoking history of at least 20 pack-years who currently smoke or quit within the past 15 years. Subanalyses of screening programs indicate lower effectiveness for SCLC compared with NSCLC. Even when detected through screening, most cases present with metastatic disease and do not demonstrate improved survival outcomes.[56]

Pearls and Other Issues

The following factors should be kept in mind when managing SCLC:

• Tarlatamab (FDA approved May 2024) is a completely new mechanism: Tarlatamab is a DLL3-targeted bispecific T-cell engager that simultaneously binds DLL3 on SCLC tumor cells and CD3 on cytotoxic T cells, triggering tumor cell killing by direct T-cell engagement. Entirely distinct from checkpoint inhibition, which releases the T-cell brake (40% ORR in DeLLphi-301). Available at relapse alongside topotecan and lurbinectedin.[34]

• According to the ADRIATIC trial (2024), use durvalumab, not tremelimumab: Durvalumab consolidation following CRT is now standard of care in limited-stage SCLC (median overall survival 55.9 versus 33.4 months versus placebo; HR 0.73). Tremelimumab added to durvalumab showed NO additional survival benefit. First major limited-stage SCLC advance in 30 years.[3]

• Don't miss SVCO and treat it correctly: Facial swelling, plethora, distended neck veins, and breathlessness in a smoker with a mediastinal mass are signs of SVCO until proven otherwise. A positive Pemberton sign (facial congestion, cyanosis, and respiratory distress when raising the arms to 180 degrees) confirms SVC compromise. The initial treatment is urgent systemic chemotherapy, not chemoradiotherapy, which is the standard for limited-stage disease only.[48]

• Lambert-Eaton versus myasthenia gravis has direct therapeutic implications:

  • Lambert-Eaton myasthenic syndrome (SCLC): weakness paradoxically improves with repeated use; legs more than arms; autonomic features in 75%; presynaptic VGCC antibodies; first-line symptomatic treatment is amifampridine (3,4-DAP).
  • Myasthenia gravis (thymoma): weakness worsens with use; ocular/bulbar predominance; acetylcholine receptor antibodies.[50]

• Paraneoplastic syndromes may precede the cancer diagnosis by months: SCLC is the most common solid tumor to cause paraneoplastic syndromes. Lambert-Eaton myasthenic syndrome, SIADH, or Cushingoid features in a current or former smoker should trigger urgent SCLC workup, even before a chest x-ray mass is visible.[50]

• Central location is the rule, while peripheral SCLC is a red flag: SCLC virtually always presents as a central hilar mass with bulky mediastinal lymphadenopathy. Peripheral SCLC should immediately raise suspicion of histological transformation from EGFR-mutant NSCLC, a well-recognised TKI resistance mechanism. Rebiopsy mandatory; pivot treatment to SCLC-directed chemo-immunotherapy.[57]

• SCLC is a smoking disease, and eGFR is not EGFR: Approximately 95% of SCLC cases are tobacco-associated. EGFR (epidermal growth factor receptor), the lung cancer oncogene, must not be confused with eGFR (estimated glomerular filtration rate), a measure of renal function. Confusing these in documentation or prescribing has direct clinical consequences.[57][9] 

  • PCI is no longer mandatory in extended-stage SCLC; MRI surveillance is an acceptable alternative: Following JCOG0504 (noninferiority of MRI surveillance vs PCI), NCCN (2024) and ESMO (2023) both endorse MRI surveillance, particularly given PCI's well-documented neurocognitive toxicity.[31] In limited-stage SCLC, the MAVERICK trial is actively evaluating this. Individualize the decision with each patient.[39][ClinicalTrials.gov. MAVERICK Trial]

Enhancing Healthcare Team Outcomes

Small cell lung cancer is a highly aggressive, high-grade neuroendocrine malignancy strongly associated with tobacco exposure and characterized by rapid growth, early metastasis, and poor survival. Molecular features include loss of RB1 and TP53 mutations, contributing to unchecked proliferation and impaired apoptosis. Patients commonly present with cough, dyspnea, hemoptysis, weight loss, or paraneoplastic syndromes, although many have metastatic disease at diagnosis. Evaluation includes contrast-enhanced CT of the thorax, PET-CT for staging, and brain MRI, with histopathologic confirmation via bronchoscopic or image-guided biopsy. Management depends on stage, with concurrent chemoradiotherapy and consolidation immunotherapy for limited-stage disease and palliative chemo-immunotherapy for extensive-stage disease, alongside supportive care and smoking cessation.

Interprofessional collaboration improves outcomes through coordinated, patient-centered care. Physicians and advanced practitioners direct diagnosis, staging, and treatment selection, while primary care clinicians promote early detection, risk reduction, and continuity of care. Medical oncologists, clinical oncologists, radiation oncologists, and thoracic surgeons ensure that treatment modalities are appropriate and proportional to the disease. Nurses monitor symptoms, treatment tolerance, and complications. Radiologists and pathologists ensure accurate diagnosis and staging, and oncology specialists guide therapy. Clinical pharmacists play a vital and often underappreciated role in SCLC management, as they are essential for monitoring cisplatin-related nephrotoxicity and electrolyte disturbances, managing immune-related adverse events from checkpoint inhibitors (including immunotherapy-related pneumonitis, colitis, and endocrinopathies), optimizing antiemetic regimens, adjusting doses for renal and hepatic impairment, and reviewing polypharmacy in this predominantly older adult patient population.Given that the majority of SCLC patients present with extensive-stage disease that is not curable, early integration of palliative care is a critical interprofessional priority. Palliative care involvement from the time of diagnosis, rather than being reserved for end-of-life care, has been shown to improve quality of life, reduce unnecessary interventions, and support advance care planning. All patients with advanced SCLC should have access to specialist palliative care as part of their interprofessional team. Effective communication, shared decision-making, timely referral, and structured follow-up reduce complications, enhance adherence, and support comprehensive care delivery.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Cittolin-Santos GF, Knapp B, Ganesh B, Gao F, Waqar S, Stinchcombe TE, Govindan R, Morgensztern D. The changing landscape of small cell lung cancer. Cancer. 2024 Jul 15;130(14):2453-2461. [PubMed: 38470453]

2.

Wang Q, Gümüş ZH, Colarossi C, Memeo L, Wang X, Kong CY, Boffetta P. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J Thorac Oncol. 2023 Jan;18(1):31-46. [PMC free article: PMC10797993] [PubMed: 36243387]

3.

Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, Lee KH, Wang Q, Navarro A, Bernabe R, Buchmeier EL, Chang JW, Shiraishi Y, Sezgin Goksu S, Badzio A, Shi A, Daniel DB, Hoa NTT, Zemanova M, Mann H, Gowda H, Jiang H, Senan S., ADRIATIC Investigators. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024 Oct 10;391(14):1313-1327. [PubMed: 39268857]

4.

Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025 Jun 03;333(21):1906-1917. [PubMed: 40163214]

5.

Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, Nabet BY, Fujimoto J, Solis LM, Lu W, Xi Y, Cardnell RJ, Wang Q, Fabbri G, Cargill KR, Vokes NI, Ramkumar K, Zhang B, Della Corte CM, Robson P, Swisher SG, Roth JA, Glisson BS, Shames DS, Wistuba II, Wang J, Quaranta V, Minna J, Heymach JV, Byers LA. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 Mar 08;39(3):346-360.e7. [PMC free article: PMC8143037] [PubMed: 33482121]

6.

Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999 Jul 21;91(14):1194-210. [PubMed: 10413421]

7.

Islami F, Nargis N, Liu Q, Bandi P, Siegel RL, Choudhury PP, Freedman ND, Warner KE, Jemal A. Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970-2022. CA Cancer J Clin. 2025 May-Jun;75(3):216-225. [PMC free article: PMC12061630] [PubMed: 40131130]

8.

Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D, Van Schil PE, Vansteenkiste J, Reck M., ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^☆. Ann Oncol. 2021 Jul;32(7):839-853. [PMC free article: PMC9464246] [PubMed: 33864941]

9.

Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 Feb 01;37(4):278-285. [PMC free article: PMC7001776] [PubMed: 30550363]

10.

Popper H, Brcic L, Eidenhammer S. Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection? Transl Lung Cancer Res. 2023 Dec 26;12(12):2412-2426. [PMC free article: PMC10775006] [PubMed: 38205203]

11.

Dwyer-Hemmings L, Fairhead C. The diagnostic performance of chest radiographs for lung malignancy in symptomatic primary-care populations: A systematic review and meta-analysis. BJR Open. 2021;3(1):20210005. [PMC free article: PMC8327929] [PubMed: 34381948]

12.

Ost DE, Jim Yeung SC, Tanoue LT, Gould MK. Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e121S-e141S. [PMC free article: PMC4694609] [PubMed: 23649435]

13.

National Lung Screening Trial Research Team. Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013 May 23;368(21):1980-91. [PMC free article: PMC3762603] [PubMed: 23697514]

14.

Santamaria S, Cardinali B, Rovere M, Marconi S, Nardin S, Sacco G, Barcellini L, Del Mastro L, Genova C, Coco S. New insight in early detection and precision medicine in small cell lung cancer: liquid biopsy as innovative clinical tool. Crit Rev Clin Lab Sci. 2025 Sep;62(6):404-428. [PubMed: 40418084]

15.

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV., IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 06;379(23):2220-2229. [PubMed: 30280641]

16.

Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e142S-e165S. [PubMed: 23649436]

17.

Khurshid H, Ismaila N, Bian J, Dabney R, Das M, Ellis P, Feldman J, Hann C, Kulkarni S, Laskin J, Manochakian R, Mishra DR, Preeshagul I, Reddy P, Saxena A, Weinberg F, Kalemkerian GP. Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline. J Clin Oncol. 2023 Dec 10;41(35):5448-5472. [PubMed: 37820295]

18.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F., CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017 Aug;18(8):1116-1125. [PMC free article: PMC5555437] [PubMed: 28642008]

19.

Simone CB, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, Jabbour SK, Kruser TJ, Schneider BJ, Slotman B, Turrisi A, Wu AJ, Zeng J, Rosenzweig KE. Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2020 May-Jun;10(3):158-173. [PMC free article: PMC10915746] [PubMed: 32222430]

20.

Kalemkerian GP, Khurshid H, Ismaila N., Systemic Therapy for Small Cell Lung Cancer Guideline Expert Panel. Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2025 Jan;43(1):101-105. [PubMed: 39565968]

21.

Liu ZL, Wang B, Liu JZ, Liu WW. Irinotecan plus cisplatin compared with etoposide plus cisplatin in patients with previously untreated extensive-stage small cell lung cancer: A meta-analysis. J Cancer Res Ther. 2018 Dec;14(Supplement):S1076-S1083. [PubMed: 30539849]

22.

Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, Brannon S, Wissel P, Ross G. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006 May 01;24(13):2044-51. [PubMed: 16648504]

23.

Lee SM, James LE, Qian W, Spiro S, Eisen T, Gower NH, Ferry DR, Gilligan D, Harper PG, Prendiville J, Hocking M, Rudd RM. Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. Thorax. 2009 Jan;64(1):75-80. [PubMed: 18786981]

24.

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW., CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. [PubMed: 31590988]

25.

Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Dec;19(12):1441-1464. [PMC free article: PMC10203822] [PubMed: 34902832]

26.

Gaebe K, Li AY, Park A, Parmar A, Lok BH, Sahgal A, Chan KKW, Erickson AW, Das S. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. Lancet Oncol. 2022 Jul;23(7):931-939. [PubMed: 35644163]

27.

Baker RR, Ettinger DS, Ruckdeschel JD, Eggleston JC, McKneally MF, Abeloff MD, Woll J, Adelstein DJ. The role of surgery in the management of selected patients with small-cell carcinoma of the lung. J Clin Oncol. 1987 May;5(5):697-702. [PubMed: 3033160]

28.

Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992 Dec 03;327(23):1618-24. [PubMed: 1331787]

29.

Virdee PS, Moschandreas J, Gebski V, Love SB, Francis EA, Wasan HS, van Hazel G, Gibbs P, Sharma RA. Protocol for Combined Analysis of FOXFIRE, SIRFLOX, and FOXFIRE-Global Randomized Phase III Trials of Chemotherapy +/- Selective Internal Radiation Therapy as First-Line Treatment for Patients With Metastatic Colorectal Cancer. JMIR Res Protoc. 2017 Mar 28;6(3):e43. [PMC free article: PMC5388825] [PubMed: 28351831]

30.

Aupérin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, Ueoka H, Wagner H, Aisner J. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999 Aug 12;341(7):476-84. [PubMed: 10441603]

31.

Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H, Nishio M, Kaneda H, Takayama K, Ishimoto O, Takeda K, Yoshioka H, Tachihara M, Sakai H, Goto K, Yamamoto N. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017 May;18(5):663-671. [PubMed: 28343976]

32.

Tsogtbaatar K, Sousa DA, Ferreira D, Tevlek A, Aydın HM, Çelik E, Rodrigues L. In vitro selection of DNA aptamers against human osteosarcoma. Invest New Drugs. 2022 Feb;40(1):172-181. [PubMed: 34383183]

33.

Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L., CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):51-65. [PubMed: 33285097]

34.

Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L., DeLLphi-301 Investigators. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023 Nov 30;389(22):2063-2075. [PubMed: 37861218]

35.

Kayama T, Sato S, Sakurada K, Mizusawa J, Nishikawa R, Narita Y, Sumi M, Miyakita Y, Kumabe T, Sonoda Y, Arakawa Y, Miyamoto S, Beppu T, Sugiyama K, Nakamura H, Nagane M, Nakasu Y, Hashimoto N, Terasaki M, Matsumura A, Ishikawa E, Wakabayashi T, Iwadate Y, Ohue S, Kobayashi H, Kinoshita M, Asano K, Mukasa A, Tanaka K, Asai A, Nakamura H, Abe T, Muragaki Y, Iwasaki K, Aoki T, Watanabe T, Sasaki H, Izumoto S, Mizoguchi M, Matsuo T, Takeshima H, Hayashi M, Jokura H, Mizowaki T, Shimizu E, Shirato H, Tago M, Katayama H, Fukuda H, Shibui S., Japan Clinical Oncology Group. Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial. J Clin Oncol. 2018 Jun 20;:JCO2018786186. [PubMed: 29924704]

36.

Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003 Jun;4(6):889-901. [PubMed: 12783586]

37.

Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T, Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A., Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009 May;10(5):467-74. [PubMed: 19386548]

38.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA., National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. [PMC free article: PMC6481621] [PubMed: 29442540]

39.

Ganti AKP, Loo BW, Badiyan S, Bassetti M, Bestvina C, Chiang A, Choudhury N, D'Avella CA, Daly M, Dowlati A, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Khalil M, Lee R, Malhotra J, Merritt RE, Mohindra N, Molina JR, Moran C, Mulvey C, Osmundson EC, Patel S, Patil T, Pokharel S, Puri S, Qin A, Sands J, Shields M, Tailor TD, Waqar SN, Cassara CJ, Ramakrishnan S. NCCN Guidelines® Insights: Small Cell Lung Cancer, Version 2.2026. J Natl Compr Canc Netw. 2026 Jan;24(1) [PubMed: 41671459]

40.

Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989 Nov;7(11):1748-56. [PubMed: 2681557]

41.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020 Aug 20;38(24):2782-2797. [PubMed: 32658626]

42.

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. [PubMed: 34724392]

43.

von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999 Feb;17(2):658-67. [PubMed: 10080612]

44.

Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 May;21(5):645-654. [PubMed: 32224306]

45.

Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, Kennedy C, Krasnik M, Peake M, Shemanski L, Bolejack V, Crowley JJ, Asamura H, Rami-Porta R., IASLC Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions. The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol. 2017 Jul;12(7):1109-1121. [PubMed: 28461257]

46.

Li X, Xu T, Jian X. Advanced small cell lung cancer with severe hyponatremia: a case report and literature review. Front Oncol. 2025;15:1558986. [PMC free article: PMC12464491] [PubMed: 41018077]

47.

Drapkin BJ, Morrell DJ, Grebla R, Shechter G, Gerber DE. Marked under-diagnosis of Lambert-Eaton myasthenic syndrome in small cell lung cancer: an analysis of real-world claims data. Front Oncol. 2025;15:1650373. [PMC free article: PMC12575191] [PubMed: 41179675]

48.

Wright K, Digby GC, Gyawali B, Jad R, Menard A, Moraes FY, Wijeratne DT. Malignant Superior Vena Cava Syndrome: A Scoping Review. J Thorac Oncol. 2023 Oct;18(10):1268-1276. [PubMed: 37146753]

49.

Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database Syst Rev. 2013 Jul 31;(7):CD009955. [PubMed: 23904353]

50.

Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011 Dec;10(12):1098-107. [PubMed: 22094130]

51.

Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J., ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-1238. [PubMed: 36270461]

52.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42. [PubMed: 20818875]

53.

National Lung Screening Trial Research Team. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 04;365(5):395-409. [PMC free article: PMC4356534] [PubMed: 21714641]

54.

de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020 Feb 06;382(6):503-513. [PubMed: 31995683]

55.

Wolf AMD, Oeffinger KC, Shih TY, Walter LC, Church TR, Fontham ETH, Elkin EB, Etzioni RD, Guerra CE, Perkins RB, Kondo KK, Kratzer TB, Manassaram-Baptiste D, Dahut WL, Smith RA. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024 Jan-Feb;74(1):50-81. [PubMed: 37909877]

56.

Thomas A, Pattanayak P, Szabo E, Pinsky P. Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening. Chest. 2018 Dec;154(6):1284-1290. [PMC free article: PMC6335258] [PubMed: 30080997]

57.

Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017 Dec;19(12):991-1002. [PMC free article: PMC5678742] [PubMed: 29091800]

Disclosure: Jonathan Pincott declares no relevant financial relationships with ineligible companies.

Disclosure: Venkatkiran Kanchustambham declares no relevant financial relationships with ineligible companies.